Product Description
Mechanisms of Action: TLR4 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Sepsis
Phase 2: Insulin Resistance|Shock, Septic
Phase 1: Leukemia|Sepsis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Eritoran2 | P2 |
Terminated |
Insulin Resistance |
2018-09-01 |
|
| 2010-020204-30 | P1 |
Terminated |
Sepsis |
2011-02-09 |
|
| ACCESS | P3 |
Completed |
Sepsis |
2011-01-01 |
|
| ACCESS | P3 |
Completed |
Sepsis |
2010-09-30 |